Skip to content

Platelets and Plasma Lipids Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis

Development and Validation of a New Method to Valuate the Platelet-Plasma Lipid Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07774845
Enrollment
45
Registered
2026-08-19
Start date
2026-03-05
Completion date
2026-11-01
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardio Vascular Disease

Brief summary

The objective of this clinical trial is to compare the effect of two different lipid emulsion formulations versus no emulsion on platelet aggregation in individuals without a history of ischemic disease. The hypothesis of this study is: Platelet aggregation is inversely associated with higher plasma lipid concentrations. The researchers will compare platelet aggregation in the presence and absence of lipid nanoemulsions in vitro through three pathways using the agonists collagen, adenosine diphosphate, and arachidonic acid. The tests will be performed using light-transmission aggregometry. Various participant parameters, such as lipid profile, will be evaluated to analyze possible correlations with the observed results. Participants must: Meet the study's inclusion criteria; Sign the informed consent form; Report to the blood draw laboratory at InCor's AB on the scheduled date and time after fasting for at least 8 hours.

Detailed description

A prospective case-control study in which the selected volunteers will serve as their own controls. Participant Selection: Volunteers with no known atherosclerotic disease will be selected from among employees of InCor/HCFMUSP and, if necessary, from the donor waiting list of the HCFMUSP blood bank.

Interventions

None listed

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men and women aged ≥ 40 years. * Willingness to sign the informed consent form. * Absence of known atherosclerotic disease

Exclusion criteria

* Use of antiplatelet agents. * Use of anticoagulants. * Use of lipid-lowering agents. * Use of oral hypoglycemic agents or insulin. * Known atherosclerotic disease. * Refusal to sign the informed consent form

Design outcomes

Primary

MeasureTime frameDescription
Effect of Lipid Emulsions on Platelet Aggregation Assessed by Optical AggregometryDay 1 (single blood sample collection)Comparison of the effect of different lipid emulsion formulations versus no emulsion (control) on platelet aggregation in blood samples from individuals without a history of ischemic disease.

Countries

Brazil

Contacts

CONTACTJosé C Nicolau, Senior Professor
jose.nicolau@fm.hc.usp.br11971514117
CONTACTJuliana L L F Regueira, Postdoctoral Res. Associate
julianaliraregueira@gmail.com11959564983

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026